In our cohort , treatment-naive BA patients with HCV-4 who were treated with peg-IFN and ribavirin had a much lower SVR rate than treatment-naive non-BA patients with HCV-4 who were treated with peg-IFN and ribavirin , and a higher relapse rate , possibly related to a weaker response to interferon-based therapy .